🗳️Your Voice Can Save Lives—Vote Now!

Vote for the Right to Trial & FDA Upgrade Act

With 95% of diseases lacking FDA-approved treatments and patients enduring 17 years of suffering, it's time for change. Help us open-source FDA.gov!

This act will give suffering patients the right to join clinical trials for promising new therapies, slashing research timelines and costs, and making all treatment data open and transparent.

If passed, this act will:
  • Open FDA.gov to public contribution, like Wikipedia for treatments
  • Let any patient join trials for promising new therapies
  • Integrate with hospitals and doctors so you can access trials through your regular care
  • Make all treatment data open and transparent for everyone
✨ Check out these great features!

How FDA v2 Can Transform Patient Access to New Treatments

FDA v2 is inspired by the , which proved that faster, more affordable, and more inclusive clinical trials are possible.

Current System
FDA v2
Cost to Test Each Patient
$41,000
$500
How Long Until Results?
17 years
100 days
Who Can Join?
Only 15% of patients
Everyone
Lives Saved or Improved
Limited
1M+
Why This Matters: With FDA v2, more people get help, faster, and at a fraction of the cost.

Should patients be allowed to join clinical trials for promising new treatments?

How it Works For Research Partners

Create a Trial

Upload protocols, pre/post-clinical data, and register your supply chain through the FDA.gov V2's intuitive interface.

  • Simple protocol builder with templates
  • Automated regulatory compliance checks
  • Secure data storage and management
Create New Trial
Upload Protocol

Get Liability Insurance

Automatically receive and select liability insurance quotes per subject with transparent pricing.

  • Competitive quotes from multiple providers
  • Risk-based pricing tailored to your trial
  • One-click policy activation
Select Liability Insurance
SafeTrial Liability Insurance
Comprehensive coverage
Recommended
Per participant:$45
MedSecure Plus
Basic coverage
Per participant:$32

Set Parameters

Define patient pricing, required data collection, and refundable deposits to optimize your trial.

  • Flexible pricing models for participants
  • Customizable data collection requirements
  • Incentive structures to maximize retention
Trial Parameters
USD
%
Blood Glucose
Weight
Activity
Diet

Manage Supply Chain & Orders

Track inventory, fulfill patient orders, and manage the entire treatment supply chain with end-to-end visibility.

  • Automated inventory tracking and alerts
  • Secure patient order processing and fulfillment
  • Temperature-controlled shipping monitoring
  • Blockchain-verified chain of custody
Supply Chain Dashboard
Inventory Status
In Stock
1,250 units
Allocated
840 units
Recent Orders
#ORD-2845
2 units • Processing
New
#ORD-2844
1 unit • Shipped
Delivered
Supply Chain Map
Interactive map view

Analyze Trial Data

Access real-time insights, analyze effectiveness data, and make informed decisions with comprehensive dashboards and reporting tools.

  • Real-time effectiveness monitoring
  • Participant compliance tracking
  • Advanced statistical analysis tools
  • Regulatory submission preparation
Trial Analytics Dashboard
Trial Performance
Effectiveness graph
Patient Compliance
Overall Rate
92%
Submissions
4,265
Adverse Events
Total Reports
12
Requires Review
3

Should patients be allowed to join clinical trials for promising new treatments?

How it Works For Patients

Find the Most Promising Treatment for Your Condition

Search for trials based on your condition, location, and preferences.

  • Access trials from anywhere in the world
  • Filter by condition, treatment type, and more
  • See real-time availability and enrollment status
  • Compare multiple treatment options side-by-side
Alzheimer's
Comparative Effectiveness Rankings
Click any treatment to view available trials
Lecanemab (Leqembi)
FDA Approved
92%
Donanemab
Phase 3
88%
Aducanumab (Aduhelm)
FDA Approved
76%
Experimental Tau Inhibitor
Phase 2
72%
Memantine + Donepezil
FDA Approved
68%
APOE4 Gene Therapy
Phase 2
65%
Neuroinflammation Modulator
Phase 2
61%
Donepezil (Aricept)
FDA Approved
58%
Memantine (Namenda)
FDA Approved
52%
Rivastigmine (Exelon)
FDA Approved
49%
Galantamine (Razadyne)
FDA Approved
47%
Stem Cell Therapy
Phase 1
45%
GLP-1 Receptor Agonist
Phase 2
42%

View Outcome Labels

Review comprehensive outcome data before deciding to join a trial.

  • See real effectiveness data from actual patients
  • Understand potential side effects and their frequency
  • Compare with standard of care treatments
  • Read about experiences from patients like you
Klotho-Increasing Gene Therapy
Cognitive Improvements (Example)
Cognitive Function (ADAS-Cog)
+28%
Memory Recall
+35%
Executive Function
+22%
Hippocampal Volume
+15%
Side Effects (Example)
Immune Response
+12%
Headache
+9%
Fatigue
+7%

Join a Trial

Complete informed consent and enroll in your chosen trial.

  • Simple digital enrollment process
  • Clear explanation of trial requirements
  • Transparent compensation information
  • Easy withdrawal option if needed
Informed Consent
I understand that I am enrolling in a clinical trial for a new Alzheimer's disease treatment.
I have reviewed the outcome label
I understand the potential risks
I agree to share my anonymized data
Complete Enrollment

Coordinate Your Care

Schedule lab tests, provider visits, and import your health records.

  • Book appointments with just a few clicks
  • Import data from your existing health records
  • Attend virtual check-ins from anywhere
  • Receive reminders for upcoming appointments
Your Care Schedule
Cognitive Assessment
Neurology Center
May 15, 2023
9:30 AM
Virtual Check-in
Dr. Robert Chen, Neurologist
May 22, 2023
2:00 PM
Join Now
Import Health Records
Schedule New Appointment

Track Your Data

Record your diet, treatment adherence, symptoms, and more.

  • Simple mobile app for daily tracking
  • Automatic data collection from wearables
  • Customized tracking based on your trial
  • Secure and private data storage
Daily Tracking
Cognitive Function
Today's score:
/ 30
Medication Taken
Morning dose
Evening dose
Daily Activities
Completed memory exercises
Completed physical activity

Gain Personal Insights

View personalized analytics about your health and treatment response.

  • See how your response compares to others
  • Identify patterns in your symptoms and triggers
  • Track your progress over time
  • Receive personalized recommendations
Your Treatment Response
Cognitive Function Trend
↑ 15%
Apr 1Apr 7
Insight
Your cognitive function scores improve on days following social activities.
Recommendation
Consider taking your medication in the evening to reduce the daytime fatigue you've reported.

Connect with Your FDAi AI Agent

Receive personalized daily check-ins from your FDAi AI agent that monitors your progress, collects data, and provides insights in a conversational way.

  • Daily check-ins via phone or text to monitor your well-being
  • Natural conversation interface for easy data collection
  • Personalized insights based on your treatment response
  • Immediate alerts for potential side effects or concerns
  • Medication reminders and adherence support

FDAi Agent

Your personal health assistant

Good morning, Sarah! How are you feeling today after your treatment yesterday?

I'm feeling better today. The headache is gone but I still feel a bit tired.

That's good progress! Your fatigue has decreased by 40% since last week. Would you like to see how your symptoms compare to others in your trial?

Yes, please show me.

Daily check-ins help track your progress and provide personalized insights

Should patients be allowed to join clinical trials for promising new treatments?

Fun Facts

Why We Desperately Need to Upgrade the FDA

The current medical research and approval system is demonstrably failing humanity. These statistics paint a clear, grim picture of the crisis, underscoring the urgent need for a decentralized, open, and patient-centric dFDA.

🚀

80X Potential Acceleration

In medical progress via an upgraded, decentralized FDA.gov.

👥

$41,000 Cost Per Participant

The staggering expense in traditional clinical trials.

💸

$1.6 Billion Development Cost

For a new treatment, a burden often falling on patients.

☠️

21K-120K Preventable Deaths

Per decade, due to sheer inefficiency in regulatory processes.

🚫

85% of Patients Excluded

From participating in vital clinical trials, denying them hope and data.

💊

95% of Diseases Untreated

Lacking any FDA-approved treatments, leaving millions in despair.

🤒

17 Years of Suffering

The average, agonizing wait from treatment discovery to patient access.

⚛️

166 Billion Untested Treatments

The vast ocean of potential cures left unexplored due to a broken system.

🌍

2 Billion People Suffering

Globally, from diseases that remain uncured, a silent pandemic.

🧫

44+ Years Since Last Disease Cure

Highlighting the profound stagnation in eradicating major diseases.

Should patients be allowed to join clinical trials for promising new treatments?

Comparative Effectiveness Rankings

Explore evidence-based rankings of interventions for various conditions

Interventions by Condition

Ranked by effectiveness based on clinical trials and real-world evidence

Metformin

87%

Effectiveness

Based on 245 trials with 35,000 participants

Gastrointestinal: 25%
B12 deficiency: 6%
Join Trial

GLP-1 Receptor Agonists

82%

Effectiveness

Based on 178 trials with 28,000 participants

Nausea: 28%
Vomiting: 10%
Join Trial

SGLT2 Inhibitors

79%

Effectiveness

Based on 156 trials with 24,000 participants

UTI: 8%
Genital infection: 5%
Join Trial

DPP-4 Inhibitors

72%

Effectiveness

Based on 189 trials with 30,000 participants

Headache: 5%
Nasopharyngitis: 4%
Join Trial

Sulfonylureas

68%

Effectiveness

Based on 210 trials with 32,000 participants

Hypoglycemia: 20%
Weight gain: 15%
Join Trial

Data updated: June 2025

Should patients be allowed to join clinical trials for promising new treatments?

Outcome Labels

FDA.gov v2 can provide standardized 'Outcome Labels' for all treatments, offering clear, quantitative data on benefits and risks. This transparency empowers patients and doctors to make informed decisions, especially when considering participation in clinical trials under a 'Right to Trial' framework.

  • Comprehensive health impact data
  • Both positive and negative effects
  • Evidence-based decision making
Atorvastatin 20mg dailyLipid-lowering agent
Primary Outcomes
LDL Cholesterol(baseline: 160 mg/dL)
-43% (-69 mg/dL)
Total Cholesterol(baseline: 240 mg/dL)
-32% (-77 mg/dL)
Cardiovascular Event Risk(10-year risk)
-36% (-4.2%)
Secondary Benefits
HDL Cholesterol
+5% (+2.3 mg/dL)
Triglycerides
-22% (-35 mg/dL)
Side Effects
Muscle Pain/Weakness(vs. placebo)
+8.2% (NNH: 12)
Liver Enzyme Elevation
+1.2% (NNH: 83)
Headache
+3.8% (NNH: 26)

Source information not available.

Last updated: Feb 2025
NNH = Number Needed to Harm (patients treated for one additional adverse event)
Your Voice Matters

Vote on The Right to Trial & FDA Upgrade Act

Do you support the following proposals?

Making FDA.gov an open-source platform that ranks treatments and provides Outcome Labels based on the universe of clinical and real-world evidence.
Granting patients the RIGHT to effortlessly participate in trials of the most promising treatments from home at their own expense (and subsidized by the NIH) continually improving the results.